Later-Line Options for Patients With PSMA-Positive mCRPC

home / case-based-roundtable-series / later-line-options-for-patients-with-psma-positive-mcrpc

This roundtable series evaluates radioligand therapy in patients with previously treated metastatic castration-resistant prostate cancer with positive prostate-specific membrane antigen, as discussed by participants at virtual live events.

Targeted Radioligand Therapy Shows Efficacy in PSMA-Positive mCRPC

Targeted Radioligand Therapy Shows Efficacy in PSMA-Positive mCRPC

Michael J. Morris, MD
July 25th 2022

Michael J. Morris, MD, discusses the results of the VISION trial of 177-lutetium-PSMA-61 in patients with metastatic castration-resistant prostate cancer.

Expert Discusses When to Perform PSMA PET Imaging for Metastatic CRPC

Expert Discusses When to Perform PSMA PET Imaging for Metastatic CRPC

Daniel George, MD
August 24th 2022

Daniel J. George, MD, discusses why he considers using prostate-specific membrane antigen imaging early in treatment of patients with castration-resistant prostate cancer.